epoetinas alfa - search results

European Union - English - EMA (European Medicines Agency)

epoetin alfa hexal

hexal ag - epoetin alfa - anemia; kidney failure, chronic; cancer - antianemic preparations - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients: , treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis;, treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. , treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy).,

United States - English - NLM (National Library of Medicine)

aranesp- darbepoetin alfa injection, solution aranesp- darbepoetin alfa solution

amgen inc - darbepoetin alfa (unii: 15uq94pt4p) (darbepoetin alfa - unii:15uq94pt4p) - darbepoetin alfa 10 ug in 0.4 ml - aranesp is indicated for the treatment of anemia due to chronic kidney disease (ckd), including patients on dialysis and patients not on dialysis. aranesp is indicated for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy. aranesp has not been shown to improve quality of life, fatigue, or patient well-being. aranesp is not indicated for use: • in patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy. • in patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure. • in patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion. • as a substitute for rbc transfusions in patients who require immediate correction o